Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 5/20 | 0.69 |
| ▸ | USP2 | O75604 | 3/20 | 0.69 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.69 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.69 |
| ▸ | RECQL | P46063 | 2/20 | 0.69 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.69 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.69 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.69 |
| ▸ | EGFR | P00533 | 1/20 | 0.69 |
| ▸ | LCK | P06239 | 1/20 | 0.69 |
| ▸ | FYN | P06241 | 1/20 | 0.69 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.69 |
| ▸ | HTR2A | P28223 | 1/20 | 0.69 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.69 |
| ▸ | CDK1 | P06493 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 3/20 | 0.51 |
| ▸ | ALPI | P09923 | 1/20 | 0.50 |
| ▸ | XIAP | P98170 | 1/20 | 0.50 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11674803 | 1.00 | SLC7A5 (0.69) | SLC7A5USP2PTGS1KDM4EALOX15 | |
| SCHEMBL29733305 | 1.00 | SLC7A5 (0.69) | SLC7A5USP2PTGS1KDM4EALOX15 | |
| Hydrochloric Acid SCHEMBL11673446 | 0.98 | SLC7A5 (0.67) | SLC7A5USP2PTGS1KDM4EALOX15 | |
| Threonine SCHEMBL17438165 | 0.89 | SLC7A5 (0.56) | SLC7A5USP2PTGS1KDM4EALOX15 | |
| SCHEMBL22057183 | 0.83 | CDK1 (0.51) | SLC7A5USP2PTGS1KDM4EALOX15 | |
| Levodopa SCHEMBL28209611 | 0.83 | SLC7A5 (0.87) | SLC7A5USP2PTGS1KDM4EALOX15 | |
| SCHEMBL17202759 | 0.82 | SLC7A5 (0.53) | SLC7A5USP2PTGS1KDM4EALOX15 | |
| SCHEMBL17202762 | 0.82 | SLC7A5 (0.53) | SLC7A5USP2PTGS1KDM4EALOX15 | |
| Levodopa SCHEMBL11000382 | 0.82 | SLC7A5 (1.00) | SLC7A5USP2PTGS1KDM4EALOX15 | |
| Levodopa SCHEMBL116907 | 0.82 | SLC7A5 (1.00) | SLC7A5USP2PTGS1KDM4EALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117642185-A | Improved CD30 targeting antibody drug conjugates and uses thereof | 路德维希-马克西米利安慕尼黑大学 | 2024-03-01 | — | — | CN | claimed |
| EP-4267193-A1 | IMPROVED CD30 TARGETING ANTIBODY DRUG CONJUGATES AND USES THEREOF | Ludwig-Maximilians-Universität München (DE) | 2023-11-01 | — | — | EP | claimed |
| WO-2022136555-A9 | IMPROVED CD30 TARGETING ANTIBODY DRUG CONJUGATES AND USES THEREOF | LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN (DE) | 2022-09-22 | — | — | WO | claimed |
| WO-2022136555-A1 | IMPROVED CD30 TARGETING ANTIBODY DRUG CONJUGATES AND USES THEREOF | LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN (DE) | 2022-06-30 | — | — | WO | claimed |
| US-20220193251-A1 | CD30 TARGETING ANTIBODY DRUG CONJUGATES AND USES THEREOF | LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN (DE) | 2022-06-23 | — | — | US | claimed |
| US-10208084-B2 | Means and methods for site-specific functionalization of polypeptides | LUDWIG-MAXIMILIANS-UNIVERSITÄT MÜNCHEN (DE) | 2019-02-19 | — | — | US | claimed |
| US-20170349625-A1 | MEANS AND METHODS FOR SITE-SPECIFIC FUNCTIONALIZATION OF POLYPEPTIDES | FORSCHUNGSVERBUND BERLIN E.V. (DE) | 2017-12-07 | — | — | US | claimed |
| EP-3212659-A1 | MEANS AND METHODS FOR SITE-SPECIFIC FUNCTIONALIZATION OF POLYPEPTIDES | Ludwig-Maximilians-Universität München (DE) | 2017-09-06 | — | — | EP | claimed |
| WO-2016066749-A1 | MEANS AND METHODS FOR SITE-SPECIFIC FUNCTIONALIZATION OF POLYPEPTIDES | LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN (DE) | 2016-05-06 | — | — | WO | claimed |
| EP-0483261-A1 | HIRUDIN PEPTIDE DERIVATIVES | BIOGEN, INC. (US) | 1992-05-06 | — | — | EP | claimed |
| WO-1991001328-A1 | HIRUDIN PEPTIDE DERIVATIVES | BIOGEN, INC. (US) | 1991-02-07 | — | — | WO | claimed |
| EP-3688007-B1 | BIOCONJUGATION OF POLYPEPTIDES | UNIV YORK (GB) | 2024-07-31 | — | — | EP | disclosed |
| US-11958880-B2 | Means and methods for site-specific functionalization of polypeptides | LUDWIG-MAXIMILIANS-UNIVERSITÄT MÜNCHEN (DE) | 2024-04-16 | — | — | US | disclosed |
| CN-117642185-A | Improved CD30 targeting antibody drug conjugates and uses thereof | 路德维希-马克西米利安慕尼黑大学 | 2024-03-01 | — | — | CN | disclosed |
| US-11897917-B2 | Bioconjugation of polypeptides | THE UNIVERSITY OF YORK (GB) | 2024-02-13 | — | — | US | disclosed |
| EP-0482069-A1 | COMBINATIONS AND METHODS FOR TREATING OR PREVENTING THROMBOTIC DISEASES | BIOGEN, INC. (US) | 1992-04-29 | — | — | EP | disclosed |
| WO-1991002750-A1 | NOVEL INHIBITORS OF THROMBIN | BIOGEN, INC. (US) | 1991-03-07 | — | — | WO | disclosed |
| WO-1991001328-A1 | HIRUDIN PEPTIDE DERIVATIVES | BIOGEN, INC. (US) | 1991-02-07 | — | — | WO | disclosed |
| WO-1991001142-A1 | COMBINATIONS AND METHODS FOR TREATING OR PREVENTING THROMBOTIC DISEASES | BIOGEN, INC. (US) | 1991-02-07 | — | — | WO | disclosed |
| US-4022910-A | L-3-hydroxymethyltyrosine and salts thereof for lowering blood pressure | RICHARDSON-MERRELL INC. (US) | 1977-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170349625-A1 | MEANS AND METHODS FOR SITE-SPECIFIC FUNCTIONALIZATION OF POLYPEPTIDES | PTMS, DNPEP, LNPEP | SLC7A5 674/4885USP2 1380/4885PTGS1 4863/4885 |
| US-11897917-B2 | Bioconjugation of polypeptides | PTMS, EPCAM, IAPP | SLC7A5 3151/4885USP2 2547/4885PTGS1 3948/4885 |
| US-10208084-B2 | Means and methods for site-specific functionalization of polypeptides | PTMS, DNPEP, LNPEP | SLC7A5 674/4885USP2 1380/4885PTGS1 4863/4885 |
| US-11958880-B2 | Means and methods for site-specific functionalization of polypeptides | PTMS, DNPEP, LNPEP | SLC7A5 674/4885USP2 1380/4885PTGS1 4863/4885 |
| US-20220193251-A1 | CD30 TARGETING ANTIBODY DRUG CONJUGATES AND USES THEREOF | TUBB6, GALNT10, TUBB | SLC7A5 451/4885USP2 3052/4885PTGS1 4867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.